BLA 020367 · Genzyme
Cerezyme
Imiglucerase · Injection · Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jan 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
May 23, 1994
Approved uses
2
Original approval plus efficacy supplements
Registered trials
49
20 Phase 3, 0 recruiting
FAERS reports
4,775
3,317 serious, 821 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate CEREZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue CEREZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING...
What it is approved for
From the label in effect Aug 27, 2026.
CEREZYME is indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients. CEREZYME is a hydrolytic lysosomal glucocerebrosidase-specific enzyme indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients. ( 1 )
Mechanism: Gaucher disease is characterized by a deficiency of β-glucocerebrosidase activity, which results in accumulation of glucocerebroside in various tissues including liver, spleen, and bone marrow. The mannose sugars on imiglucerase mediate binding to and internalization by cells including macrophages. CEREZYME catalyzes the hydrolysis of glucocerebroside to glucose and ceramide.
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 12, 2026 Supplement 123 · Efficacy OrphanLabelLetter
- May 23, 1994 Original approval · Type 1 - New Molecular Entity · priority review Other
2 products under this application
- CEREZYME · IMIGLUCERASE 400 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
- CEREZYME · IMIGLUCERASE 200 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Imiglucerase" as an intervention, any sponsor and status, largest first.
- A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene MutationPivotal-lookingTerminated
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02906020 · 273 participants · Start Dec 15, 2016 · Primary completion Dec 18, 2020
Drug: venglustat GZ/SAR402671; Placebo · For: Parkinson's Disease
Sites: Scottsdale, Arizona; La Jolla, California; Palo Alto, California · 52 sites in all
- Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDPivotal-lookingCompleted
Bial R&D Investments, S.A.Industry
NCT05819359 · 273 participants · Start Mar 31, 2023 · Primary completion Apr 2, 2026
Drug: BIA 28-6156 10 mg; BIA 28-6156 60 mg and 1 more · For: Parkinson's Disease
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 95 sites in all
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)Pivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01074944 · 170 participants · Start Jun 2010 · Primary completion Oct 2015
Drug: Eliglustat tartrate · For: Gaucher Disease
Sites: San Diego, California; New Haven, Connecticut; Decatur, Georgia · 46 sites in all
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)Pivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00943111 · 160 participants · Start Sep 2009 · Primary completion Nov 2012
Drug: Eliglustat tartrate; Imiglucerase · For: Gaucher Disease, Type 1
Sites: Beverly Hills, California; San Francisco, California; Aurora, Colorado · 34 sites in all
National Institute of Neurological Disorders and Stroke (NINDS)NIH
NCT00001416 · 100 participants · Start Dec 1993
Drug: CEREDASE™ · For: Gaucher's Disease
Sites: Bethesda, Maryland
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00364858 · 95 participants · Start Dec 2001
Drug: Cerezyme · For: Gaucher Disease, Type 1; Cerebroside Lipidosis Syndrome; Glucocerebrosidase Deficiency Disease and 2 more
Sites: Washington D.C., District of Columbia; Coral Springs, Florida; Atlanta, Georgia · 26 sites in all
- An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher DiseasePivotal-lookingCompleted
ShireTakeda (TAK)
NCT00635427 · 95 participants · Start Mar 13, 2008 · Primary completion Dec 28, 2012
Drug: VPRIV® · For: Gaucher Disease, Type 1
Sites: Los Angeles, California; Oakland, California; Atlanta, Georgia · 21 sites in all
Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaAcademic, hospital or other
NCT05287503 · 65 participants · Start Mar 9, 2022 · Primary completion Dec 15, 2024
Drug: Ambroxol Hydrochloride; Placebo · For: Parkinson Disease; GBA Gene Mutation
Sites: Milan, Italy; Naples, Italy; Pavia, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia216
- fatigue192
- death174
- fall174
- pneumonia174
- weight increased163
- exposure during pregnancy162
- dyspnoea151
- bone pain150
- weight decreased140
- malaise137
- arthralgia130
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 115 |
| 2005 | 105 |
| 2006 | 123 |
| 2007 | 164 |
| 2008 | 170 |
| 2009 | 233 |
| 2010 | 225 |
| 2011 | 262 |
| 2012 | 172 |
| 2013 | 230 |
| 2014 | 386 |
| 2015 | 273 |
| 2016 | 226 |
| 2017 | 277 |
| 2018 | 213 |
| 2019 | 202 |
| 2020 | 146 |
| 2021 | 201 |
| 2022 | 225 |
| 2023 | 213 |
| 2024 | 196 |
| 2025 | 226 |
| 2026 | 192 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cerezyme (Imiglucerase)
2024 spending
$14.3M
Beneficiaries
39
455 claims
Per beneficiary
$365,943
$1,681.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,987,685 |
| 2021 | $14,987,046 |
| 2022 | $15,732,693 |
| 2023 | $15,164,652 |
| 2024 | $14,271,795 |
Part B: Cerezyme (Imiglucerase) · HCPCS J1786
2024 spending
$44.2M
Beneficiaries
140
2,260 claims
Per beneficiary
$316,023
2024 ASP limit $43.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $35,829,480 |
| 2021 | $39,031,430 |
| 2022 | $43,717,471 |
| 2023 | $45,952,004 |
| 2024 | $44,243,279 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP).
Schiffmann R, Mengel E, Wallace M, et al. · Adv Ther 2024 · Clinical Trial, Phase II, Multicenter Study
- Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.
Berger J, Vigan M, Pereira B, et al. · Clin Pharmacokinet 2019 · Clinical Trial, Multicenter Study
- A multicenter, open-label, phase III study of Abcertin in Gaucher disease.
Lee BH, Abdalla AF, Choi JH, et al. · Medicine (Baltimore) 2017 · Clinical Trial, Phase III, Multicenter Study
- Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
Kuter DJ, Wajnrajch M, Hernandez B, et al. · Blood Cells Mol Dis 2020 · Clinical Trial, Phase III, Multicenter Study
- Replacement therapy with imiglucerase for type 1 Gaucher's disease.
Zimran A, Elstein D, Levy-Lahad E, et al. · Lancet 1995 · Clinical Trial, Comparative Study
- A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease.
Leonart LP, Fachi MM, Böger B, et al. · Ann Pharmacother 2023 · Meta-Analysis, Systematic Review
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.